Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

IDEAYA Biosciences Inc

IDYA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$39.67

▲ +1.43%

Market Cap $3.83B · Vol 279.19K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.83B

Mid Cap

Div Yield

N/A

EPS Growth

-256.13%

YoY

RSI (14)

83.94

Momentum

Beta

-0.08

vs Market

52W High

$40.58

2.24% below

52W Low

$23.24

70.73% above

Volume

279.19K

Avg 287.70K

P/B

2.97

Price-to-book

ROE

-10.92%

Return on equity

Free Float

97.81%

Public shares

Shariah Compliance8 STANDARDS

✗ IDEAYA Biosciences Inc (IDYA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IDYA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+9.28%

+10.23%

+34.29%

+24.05%

YTD

+14.75%

+61.06%

+41.93%

+67.45%

Financials & Valuation

TTM · Annual

Total Revenue	$218.71M
Net Income	$-113,698,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-72.84%
Net Profit Margin	-51.99%
ROE	-10.92%
ROA · ROIC	-10.18% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	13.99
P/B	2.97
P/FCF	N/A
EPS Growth	-256.13%
Outstanding Shares	96.49M

Technical Indicators

50-Day SMA	$35.91
200-Day SMA	$33.27
RSI (14)	83.94
Beta	-0.08
52-Week High	$40.58
52-Week Low	$23.24

Volume Today	279.19K
Avg Daily Volume (30D)	287.70K
Relative Volume	0.97x
Volatility (10D)	22.59
Volatility (30D)	29.66
Free Float	97.81%

Analyst Consensus

BUY

Current Price $39.67

Mean Target $52.62

52W Low$23.24 52W High$40.58

Current

Target

$23.24 $40.58

Current Analyst target

+32.63% upside potential · 15 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00CTZ4D92

ISINUS45166A1025

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.09% ONC BeOne Medicines AG +1.44% RVMD Revolution Medicines Inc -1.07% 068270.KS Celltrion Inc -0.93% ABVX Abivax SA -2.75%

Company Profile

IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.